Last reviewed · How we verify
NCT06907238
The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism
trial in Acute Pulmonary Embolism in 400 participants. Not yet recruiting.
30 July 2027
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 14 October 2025 |
| Primary completion | 30 July 2027 |
| Estimated completion | 31 December 2027 |
Conditions studied
- Acute Pulmonary Embolism — all drugs for Acute Pulmonary Embolism →
Sponsor
Beijing Anzhen Hospital
Who can join
Adults 18 to 120, any sex, with Acute Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In response to the high mortality rate of patients with acute pulmonary embolism (APE) and the fact that only a small proportion of deceased patients can receive correct diagnosis, this study will use a sensitive, non-invasive, and feasible new thrombus molecular marker (TAT/PIC/TM/t-PAIC) to detect and evaluate the activation of the coagulation and fibrinolysis systems and endothelial system damage in patients, in order to monitor the early diagnosis and treatment of APE, reduce mortality, and improve patient quality of life. Therefore, this study intends to include 200 newly diagnosed APE patients to evaluate the sensitivity and specificity of the single and combined application of novel thrombus molecular markers for APE diagnosis; Detect the biomarker results of patients at different time points before and after treatment, and evaluate their value in APE treatment monitoring; Track and follow up on patients after discharge to explore the prognostic value of biomarkers for APE.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06907238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Pulmonary Embolism
Currently open trials in the same condition.
- NCT07190079 — Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism · recruiting
- NCT06784492 — Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism · NA · recruiting
- NCT06038630 — 129Xe MRI Cardiopulmonary · Phase 2 · recruiting
- NCT06081205 — Study of Patients Admitted to a Cardiac Intensive Care Unit With Acute CardioVascular Disease · recruiting
- NCT04757129 — Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism · recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06907238 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06907238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing